Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases... Show more
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IIGD | 24.01 | -0.09 | -0.39% |
| Invesco Investment Grade Defensive ETF (IIGD) | |||
| DVSP | 28.04 | -0.11 | -0.39% |
| WEBs SPY Defined Volatility ETF (DVSP) | |||
| DRSK | 27.14 | -0.20 | -0.73% |
| Aptus Defined Risk ETF (DRSK) | |||
| BGIA | 24.44 | -0.21 | -0.85% |
| Baillie Gifford International Alpha ETF (BGIA) | |||
| NEBX | 7.27 | -0.83 | -10.25% |
| Tradr 2X Long NBIS Daily ETF (NEBX) | |||
A.I.dvisor indicates that over the last year, ZLAB has been loosely correlated with ALEC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if ZLAB jumps, then ALEC could also see price increases.
| Ticker / NAME | Correlation To ZLAB | 1D Price Change % | ||
|---|---|---|---|---|
| ZLAB | 100% | -1.60% | ||
| ALEC - ZLAB | 37% Loosely correlated | +2.85% | ||
| ONC - ZLAB | 36% Loosely correlated | +1.60% | ||
| ORIC - ZLAB | 34% Loosely correlated | -3.47% | ||
| AMRN - ZLAB | 33% Loosely correlated | +0.09% | ||
| VCYT - ZLAB | 32% Poorly correlated | -7.18% | ||
More | ||||
a service for cancer & autoimmune treatment
Industry Biotechnology
ZLAB saw its Momentum Indicator move above the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 77 similar instances where the indicator turned positive. In 60 of the 77 cases, the stock moved higher in the following days. The odds of a move higher are at 78%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ZLAB's RSI Indicator exited the oversold zone, 24 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for ZLAB just turned positive on November 06, 2026. Looking at past instances where ZLAB's MACD turned positive, the stock continued to rise in 32 of 42 cases over the following month. The odds of a continued upward trend are 76%.
ZLAB moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +18.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZLAB advanced for three days, in 201 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for ZLAB crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZLAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
ZLAB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZLAB entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 14 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.712) is normal, around the industry mean (3.498). P/E Ratio (-14.988) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (6.079) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. ZLAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZLAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.